Literature DB >> 19509474

Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labeling index of more than 3%.

Y Ogawa1, H Ikeda, T Tominaga.   

Abstract

BACKGROUND: Pituitary adenoma is generally indolent, but an aggressive subtype including atypical adenoma has uncertain prognosis, and an unclear relationship between prognosis and morphology. AIM: To investigate the prognostic factors of adenomas with Ki-67 labeling index of more than 3%. SUBJECTS AND METHODS: Patients with surgically treated pituitary adenomas with Ki-67 labeling index of more than 3% were retrospectively identified as 13 males and 20 females aged from 15 to 73 yr (mean 47.2 yr) among 527 patients with pituitary adenoma treated at the Department of Neurosurgery, Tohoku University and Department of Neurosurgery, Kohnan Hospital between January 2001 and December 2007.
RESULTS: The tumors included 12 cases of gross totally removed pituitary adenomas, and 21 non-totally removed adenomas. Statistical analysis found significant differences in recurrence between gross total and non-total removal (log-rank test, p<0.001), and giant adenomas had higher risk of recurrence or re-growth (log-rank test, p<0.01); 71.4% of re-growth was detected within 12 months if the patients had tumor remnants after the operation. Both immunohistochemical types of tumor and invasion of the surrounding tissue had no statistical correlation with tumor regrowth, and high Ki-67 and p53 labeling index had no relationship with duration of stable disease among these patients independently.
CONCLUSIONS: Gross total removal is the most important prognostic factor in patients with adenoma with Ki-67 labeling index of more than 3%. In contrast, giant adenoma carries higher risk of recurrence and/or re-growth. If gross total removal is not achieved immediate adjuvant therapy should be performed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19509474     DOI: 10.1007/BF03346512

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  14 in total

1.  p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.

Authors:  K Thapar; B W Scheithauer; K Kovacs; P J Pernicone; E R Laws
Journal:  Neurosurgery       Date:  1996-04       Impact factor: 4.654

Review 2.  Predictive markers of pituitary adenoma behavior.

Authors:  George Kontogeorgos
Journal:  Neuroendocrinology       Date:  2006-10-13       Impact factor: 4.914

3.  Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination.

Authors:  Kazunori Arita; Atsushi Tominaga; Kazuhiko Sugiyama; Kuniki Eguchi; Koji Iida; Masayuki Sumida; Keisuke Migita; Kaoru Kurisu
Journal:  J Neurosurg       Date:  2006-06       Impact factor: 5.115

Review 4.  Malignant prolactinoma: case report and review of the literature.

Authors:  Marleen Kars; Ferdinand Roelfsema; Johannes A Romijn; Alberto M Pereira
Journal:  Eur J Endocrinol       Date:  2006-10       Impact factor: 6.664

5.  Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody.

Authors:  K Thapar; K Kovacs; B W Scheithauer; L Stefaneanu; E Horvath; P J Pernicone; D Murray; E R Laws
Journal:  Neurosurgery       Date:  1996-01       Impact factor: 4.654

Review 6.  Clinical review: Diagnosis and management of pituitary carcinomas.

Authors:  Gregory A Kaltsas; Panagiotis Nomikos; George Kontogeorgos; Michael Buchfelder; Ashley B Grossman
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

7.  A case of atypical thyrotroph cell adenoma, which re-grew within 3 months after surgery and required multimodal treatment.

Authors:  Yoshikazu Ogawa; Teiji Tominaga
Journal:  J Neurooncol       Date:  2007-11-07       Impact factor: 4.130

Review 8.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.

Authors:  Wolfgang Saeger; Dieter K Lüdecke; Michael Buchfelder; Rudolf Fahlbusch; Hans-Jürgen Quabbe; Stephan Petersenn
Journal:  Eur J Endocrinol       Date:  2007-02       Impact factor: 6.664

9.  A survey of pituitary incidentaloma in Japan.

Authors:  Naoko Sanno; Ken'ichi Oyama; Shigeyuki Tahara; Akira Teramoto; Yuzuru Kato
Journal:  Eur J Endocrinol       Date:  2003-08       Impact factor: 6.664

10.  p53 gene mutations in pituitary adenomas: rare events.

Authors:  A Levy; L Hall; W A Yeudall; S L Lightman
Journal:  Clin Endocrinol (Oxf)       Date:  1994-12       Impact factor: 3.478

View more
  3 in total

1.  Mid-term prognosis of non-functioning pituitary adenomas with high proliferative potential: really an aggressive variant?

Authors:  Yoshikazu Ogawa; Hidefumi Jokura; Kuniyasu Niizuma; Teiji Tominaga
Journal:  J Neurooncol       Date:  2018-01-09       Impact factor: 4.130

2.  Somatostatin-producing atypical null cell adenoma manifesting as severe hypopituitarism and rapid deterioration--case report.

Authors:  Yoshikazu Ogawa; Mika Watanabe; Teiji Tominaga
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

3.  Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.

Authors:  Marialaura Del Basso De Caro; Domenico Solari; Francesca Pagliuca; Alessandro Villa; Elia Guadagno; Luigi Maria Cavallo; Annamaria Colao; Guido Pettinato; Paolo Cappabianca
Journal:  Neurosurg Rev       Date:  2016-05-23       Impact factor: 3.042

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.